-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Ranked Among the “Top 100 Chinese Chemical Pharmaceutical Enterprises”
Category:
发布时间：2023-06-28
【概要描述】
On the evening of June 27, the 2022 Mingsi Conference (China Pharmaceutical and Health Industry Symbiosis Conference) hosted by Mene.net opened in Huzhou, Zhejiang Province, where the highly anticipated 2022 Top 100 Chinese Pharmaceutical Companies ranking was unveiled. Shijiazhuang Sihua Pharmaceutical Group was recognized for its robust R&D capabilities and strong market influence, earning a place on the “2022 Top 100 Chinese Chemical Pharmaceutical Enterprises” list at No. 39.
On the evening of June 27, the 2022 Mingsi Conference (China Pharmaceutical and Health Industry Symbiosis Conference) hosted by MeneNet opened in Huzhou, Zhejiang Province, during which the highly anticipated 2022 Top 100 Chinese Pharmaceutical Companies ranking was unveiled. Shijiazhuang Sihua Pharmaceutical Group was recognized for its robust R&D capabilities and strong market influence, earning a place among the “2022 Top 100 Chinese Chemical Pharmaceutical Enterprises” at No. 39 on the list.
According to reports, as one of the most authoritative, professional, and high-profile intellectual forums in China’s pharmaceutical and health industry, this year’s MiSi Conference is themed “Quality Wins: A New Cycle.” It aims to build a platform for thought-sharing and resource collaboration by fostering brand connectivity, insightful data analysis, strategic foresight, and professional empowerment. The ranking assessment focuses on the innovation-driven capabilities and professional promotion strengths of pharmaceutical manufacturing enterprises. Specifically, innovation drive is evaluated primarily through comprehensive R&D investment metrics, while professional promotion strength is rigorously defined based on quantitative end-user data reflecting the ultimate preferences of clinicians and patients. The final results are derived from a quantitative analysis that integrates exclusive three-terminal, six-market end-user data provided by MeneNet.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has proactively built a high-performance ecosystem for R&D and innovation, aligning its innovation chain with the industrial value chain to continuously elevate the level and sophistication of its innovative development. Leveraging the Group’s resource advantages, it has accelerated the research and development of specialty generic drugs, active pharmaceutical ingredients, innovative medicines, pharmaceutical packaging materials, and products undergoing bioequivalence evaluation, thereby achieving synchronized development across the entire drug R&D–market translation value chain. This approach has enabled the Group to establish a uniquely distinctive product portfolio and cultivate new competitive advantages in the industry. Currently, the Group has nearly 200 projects in development; among them, several Class 1 new drugs, including ADN-9 for anti-liver fibrosis, have either received clinical trial approval or submitted applications for clinical trials, while more than 100 additional new products are awaiting approval. Since the beginning of this year, the Group has secured approval for 32 new products, placing it among the leaders nationwide in both the efficiency and volume of specialty generic drug R&D. The Group has also been recognized as one of the Top 30 in the 2023 China Comprehensive Pharmaceutical R&D Strength Ranking and one of the Top 10 in the 2023 China Chemical Pharmaceutical R&D Strength Ranking. With the industry’s overall scale continuing to expand, innovation outcomes becoming increasingly abundant, the product mix steadily optimized, and economic performance consistently improving, the Group is well-positioned to achieve rapid, quality-driven growth and enhanced efficiency. In 2022, the Group’s key financial indicators posted robust growth, reflecting vibrant and dynamic corporate operations.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091